Innoviva to Report First Quarter Financial Results on April 27 at 5:00 p.m. EDT
April 21 2017 - 8:00AM
Business Wire
Innoviva, Inc. (NASDAQ: INVA) announced today that it will
report financial results for the first quarter ended March 31, 2017
after market close on Thursday, April 27, 2017. Following the
earnings release, Innoviva management will host a webcast and
conference call at 5:00 p.m. EDT/2:00 p.m. PDT to discuss the
financial results and provide a corporate update.
To participate in the live call, dial (877) 837-3908 from the
U.S., or (973) 890-8166 for international callers, and enter
Conference ID: 4743061. A live webcast of the call will be
available at: http://edge.media-server.com/m/p/7vf4ydi7 or from the
investor relations section of the company website at www.inva.com
and will be archived for 30 days. A telephone replay of the call
will be available through May 3 by dialing (855) 859-2056 from the
U.S., or (404) 537-3406 for international callers, and entering
Conference ID: 4743061.
About Innoviva
Innoviva is focused on bringing compelling new medicines to
patients in areas of unmet need by leveraging its significant
expertise in the development, commercialization and financial
management of bio-pharmaceuticals. Innoviva's portfolio is anchored
by the respiratory assets partnered with Glaxo Group Limited (GSK),
including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were
jointly developed by Innoviva and GSK. Under the agreement with
GSK, Innoviva is eligible to receive associated royalty revenues
from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®. In addition, Innoviva
retains a 15 percent economic interest in future payments made by
GSK for earlier-stage programs partnered with Theravance BioPharma,
Inc., including the closed triple combination therapy for COPD. For
more information, please visit Innoviva's website at
www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the
GlaxoSmithKline group of companies.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170421005041/en/
Innoviva, Inc.Eric d'Esparbes, 650-238-9640Senior Vice President
and Chief Financial Officerinvestor.relations@inva.com
Innoviva (NASDAQ:INVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Innoviva (NASDAQ:INVA)
Historical Stock Chart
From Sep 2023 to Sep 2024